Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy Journal Article

Local Library Link: Find It @ Loyola

Authors: Gopal, A. K.; Bartlett, N. L.; Forero-Torres, A; Younes, A.; Chen, R; Friedberg, J. W.; Matous, J. V.; Shustov, A. R.; Smith, S. E.; Zain, J.; O'Meara, M. M.; Fanale, M. A.
Article Title: Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy
Abstract: Older adults constitute a significant proportion of the cancer population, but are underrepresented in clinical trials. We conducted a retrospective analysis of the safety and efficacy of brentuximab vedotin in adults >/= 60 years with relapsed CD30-positive lymphomas. Baseline characteristics and safety data were compared for older (median age 66) and younger patients (/= grade 3 (70% vs. 56%) occurred in older patients. Objective response rates were 56% and 100% in older patients with Hodgkin lymphoma and systemic anaplastic large cell lymphoma, respectively. With appropriate monitoring, brentuximab vedotin may represent a meaningful clinical option for older patients with relapsed CD30-positive lymphomas.
Journal Title: Leukemia lymphoma
Volume: 55
Issue: 10
ISSN: 1029-2403; 1026-8022
Publisher: Unknown  
Journal Place: England
Date Published: 2014
Start Page: 2328
End Page: 2334
Language: eng
DOI/URL:

10.3109/10428194.2013.876496
Notes: LR: 20150501; ClinicalTrials.gov/NCT01716806; GR: P30 CA015704/CA/NCI NIH HHS/United States; GR: P30 CA015704/CA/NCI NIH HHS/United States; JID: 9007422; 0 (Antigens, CD30); 0 (Antineoplastic Agents); 0 (Immunoconjugates); 0 (cAC10-vcMMAE); OTO: NOTNLM; 2014/02/24 [aheadofprint]; ppublish